Netherlands Cancer Insitute
🇳🇱Netherlands
- Country
- 🇳🇱Netherlands
- Ownership
- Private
- Established
- 1913-10-10
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nki.nl
Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphoma
Completed
- Conditions
- Non Hodgkin LymphomaDLBCLCardiovascular DiseasesCardiomyopathiesCardiotoxicityMetabolic SyndromeQuality of LifeLate EffectHeart Failure
- First Posted Date
- 2025-06-27
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 217
- Registration Number
- NCT07041827
- Locations
- 🇳🇱
Netherlands Cancer Institute, Amsterdam, North Holland, Netherlands
Functional Liver After SBRT
Not yet recruiting
- Conditions
- Liver Metastases
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT07033364
TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer
Not yet recruiting
- Conditions
- Breast Cancer
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 100
- Registration Number
- NCT06931769
- Locations
- 🇳🇱
The Netherlands Cancer Institute, Amsterdam, Netherlands
Bevacizumab Versus Corticosteroids As First-line Treatment in Patients with Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases
Phase 3
Not yet recruiting
- Conditions
- Radiation NecrosisHigh Grade Glioma (III or IV)Brain MetastasasesRadiation ToxicityRadiation EffectRadiation InjuryRadiation Injuries
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 408
- Registration Number
- NCT06888817
- Locations
- 🇳🇱
Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Netherlands
🇳🇱Amsterdam University Medical Centers, location VUmc and AMC, Amsterdam, Netherlands
🇳🇱Leiden University Medical Center, Leiden, Netherlands
PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II)
Phase 4
Recruiting
- Conditions
- Erectile Dysfunction Following Radical Prostatectomy
- Interventions
- Device: Erectile vacuum device
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 198
- Registration Number
- NCT06875258
- Locations
- 🇳🇱
Canisius Wilhelmina Ziekenhuis, Nijmegen, Gelderland, Netherlands
🇳🇱Antoni van Leeuwenhoek hospital, Netherlands Cancer Institute, Amsterdam, Noord-holland, Netherlands
🇳🇱Maasstad ziekenhuis, Rotterdam, Zuid-Holland, Netherlands
Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy with Systemic Therapy
Phase 3
Recruiting
- Conditions
- Colorectal NeoplasmsFloxuridineLiver MetastasesVascular Access Device
- Interventions
- Drug: Systemic therapy (standard of care)Drug: Intra arterial infusion Floxuridine (FUDR) combined with systemic therapyDevice: Hepatic arterial infusion pump (HAIP)
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 306
- Registration Number
- NCT06857773
- Locations
- 🇳🇱
Antoni van Leeuwenhoek-Netherland Cancer Institute, Amsterdam, Netherlands
Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial
Phase 2
Recruiting
- Conditions
- Neuroendocrine TumorsNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2Neuroendocrine Neoplasm
- Interventions
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 39
- Registration Number
- NCT06855095
- Locations
- 🇳🇱
Antoni van Leeuwenhoek, Amsterdam, Netherlands
Towards Cure Via Only Ultra-short ICB in CSCC
Phase 2
Recruiting
- Conditions
- Cutaneous Squamous Cell Carcinoma (CSCC)Cutaneous Squamous Cell CancerCutaneous Squamous Cell Carcinoma of the Head and NeckCutaneous Squamous Cell Carcinoma
- Interventions
- Drug: Ipilumimab
- First Posted Date
- 2025-02-12
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 41
- Registration Number
- NCT06823479
- Locations
- 🇳🇱
Maastricht UMC, Maastricht, Limburg, Netherlands
🇳🇱Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Noord-Holland, Netherlands
🇳🇱Amsterdam UMC, Amsterdam, Noord-Holland, Netherlands
FeASibility of Cbct-guIded ONline Adaptive RadioThErapy
Not Applicable
Recruiting
- Conditions
- Prostate CancerCervical CancerBladder CancerLung CancerHead and Neck Cancer
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 100
- Registration Number
- NCT06691776
- Locations
- 🇳🇱
Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy
Not Applicable
Recruiting
- Conditions
- Penile CancerMelanomaOral Cancer
- Interventions
- Drug: Sentinel node biopsy with either ICG-99mTc-nanoscan or 99mTc-nanoscan
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 29
- Registration Number
- NCT06666634
- Locations
- 🇳🇱
NKI-AVL, Amsterdam, Netherlands